Cook Group Goes to School in Cell Therapy
This article was originally published in Start Up
Executive Summary
While a host of cardiovascular device companies are collaborating with gene and cell therapy firms in heart disease, Cook is taking a different approach to get in-house cell therapy expertise. It's created spin-off Cook Myosite, to develop the first cell therapy for urinary incontinence. Cook's urological division will sell the final product.